Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy
Christa E. Nath(Children's Hospital at Westmead), John Earl(Children's Hospital at Westmead), Peter Presgrave(Wollongong Hospital), Howard Gurney(Radboud University Nijmegen), Andrew J. McLachlan(The University of Sydney), Ian Kerridge(The University of Sydney), Yiu Lam Kwan(Concord Repatriation General Hospital), Campbell Tiley(Gosford Hospital), Peter J. Shaw(Children's Hospital at Westmead), Lihua Zeng(Children's Hospital at Westmead), Judith Trotman(The University of Sydney), Gareth Hegarty(University of Otago), Douglas Joshua(Royal Prince Alfred Hospital), Stephen B. Duffull(The University of Queensland)
Cited by 80
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes
|Journal of Clinical Epidemiology|2012|1.2k